Search Browse Earnings

PROVECTUS BIOPHARMACEUTICALS, INC.

OTC:PVCT

Pharmaceutical Preparations·KNOXVILLE, TN

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Pershing Edward

Revenue

$557,710

-43.6% YoY

FY 2024

Adj. EBITDA

-$2.9M

-518.6% margin

FY 2024

Net Income

-$3.1M

-556.2% margin

FY 2024

EPS (Diluted)

-$0.01

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$76,576

FY 2024

Total Debt

$500,000

FY 2013

Net Debt

$423,424

FY 2013

Enterprise Value

—

Debt / EBITDA

-0.1x

FY 2024

EV / EBITDA

—

Employees

—